{"filings":[{"id":563120,"accession_number":"0001104659-26-064754","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-05-21T10:01:46+00:00","items":["7.01"],"status":"ready","headline":"NanoViricides says NV-387 and NV-387-remdesivir expected to be effective against Ebola Bundibugyo strain in DRC","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["NV-387 is broad-spectrum antiviral entering Phase II for Mpox in DRC.","NV-387-remdesivir is an oral formulation shown in animal models; PLOS ONE paper published.","Encapsulation protects remdesivir from metabolism, improving efficacy per company.","Company has a clinical site in DRC for Mpox; public health responders to decide on Ebola.","Remdesivir was tested in prior Ebola trials but efficacy not established; antibodies approved only for Zaire strain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":555320,"accession_number":"0001104659-26-064544","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2026-05-20T20:30:33+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NanoViricides raises $2M in registered direct offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,333,334 shares (or pre-funded warrants) plus 1,333,334 warrants at $1.75, priced at $1.50 per share.","Gross proceeds $2,000,001; closed May 18, 2026; D. Boral Capital as placement agent.","Single institutional investor purchased entire offering; CEO agreed to 30-day lock-up.","Net proceeds to fund working capital, R&D, and clinical trial expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119657,"accession_number":"0001104659-25-116457","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides annual meeting approves director re-election, executive compensation, auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anil Diwan re-elected as Class I Director with 9,757,652 votes in favor, 173,096 against.","Advisory vote on executive compensation passed: 9,500,223 for, 420,374 against.","Ratification of EisnerAmper as auditor for fiscal year ending June 30, 2026 passed: 14,594,257 for, 194,416 against.","Meeting held November 22, 2025; quorum of ~61% of outstanding voting capital stock present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119656,"accession_number":"0001104659-25-112644","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NanoViricides raises $6M in registered direct offering and private placement with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 3,571,429 shares (or pre-funded equivalents) at $1.68/share for gross proceeds of ~$6M.","Concurrent private placement of Series A warrants (3.57M shares, $1.75 exercise, 2yr) and Series B warrants (3.57M shares, $2.00 exercise, 5.5yr).","Offering closed Nov 12, 2025; net proceeds for working capital and general corporate purposes.","Directors and executive officers entered into 90-day lock-up agreements following closing.","A.G.P./Alliance Global Partners acted as sole placement agent with 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119655,"accession_number":"0001104659-25-095676","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoViricides extends CEO/CFO contracts; raises CEO line of credit to $3M through 2027","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President/CEO Diwan term extended to June 30, 2026; base salary $400,000/yr; granted 10,204 Series A preferred shares vesting quarterly.","CFO Vyas term extended to June 30, 2026; compensation $10,800/month; health insurance reimbursement up to $2,500/month.","CEO Diwan's line of credit increased from $2M to $3M; maturity extended to March 31, 2027; 12% interest; secured by company property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189067,"accession_number":"0001104659-24-128066","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders re-elect three directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Theodore Rokita re-elected with 2,060,147 votes for, 166,389 against.","Makarand Jawadekar re-elected with 1,951,381 votes for, 272,416 against.","Brian Zucker re-elected with 2,088,483 votes for, 139,413 against.","EisnerAmper LLP ratified as auditor for FY ending June 30, 2025 with 5,757,913 votes for.","Meeting quorum of 47.1% with 6,096,059 common and 883,177 Series A Preferred shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205551,"accession_number":"0001104659-24-087828","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NanoViricides extends President Diwan ($400k, 10k Series A shares) and CFO Vyas through June 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["President Anil Diwan's employment extended to June 30, 2025 at $400,000 base salary.","Diwan receives 10,204 Series A Preferred shares, vesting quarterly over the one-year term.","CFO Meeta Vyas extended on same general terms; new health insurance reimbursement up to $2,500/month.","Diwan eligible for six months' severance if terminated without cause, plus continued benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222486,"accession_number":"0001104659-24-044367","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NanoViricides names EF Hutton as sole sales agent for $50M ATM, removes B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EF Hutton LLC becomes sole agent under existing $50M at-the-market offering; B. Riley Securities removed.","Company may sell shares at its discretion; no obligation to issue any shares.","Commission of 3% of gross proceeds; reimburses Agent $50k initial plus $2.5k/quarter expenses.","Sales made under effective shelf registration S-3 (No. 333-271706) and related prospectus supplements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242006,"accession_number":"0001104659-24-024973","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"NanoViricides defers TheraCour milestone payments until revenue; CEO extends Line of Credit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to TheraCour license defers future cash milestone payments (Milestones 4-7) until company achieves a Revenue Event; capped at 50% of Recognized Revenue.","Milestones 1,2,3 already paid: 100k Series A Preferred shares, 50k Series A Preferred shares, and $1.5M via 331,859 shares in lieu of cash.","CEO Dr. Anil Diwan extended $2M line of credit maturity from Dec 31, 2024 to Dec 31, 2025; no draws to date.","TheraCour agreed to suspend two-month advance payment requirement until company raises sufficient capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242005,"accession_number":"0001104659-24-005254","cik":1379006,"company_name":"NANOVIRICIDES, INC.","ticker":"NNVC","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NanoViricides shareholders re-elect Anil Diwan as director, approve executive compensation and preferred stock grant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At the January 13, 2024 annual meeting, shareholders re-elected Anil Diwan as Class I director with 5,590,467 votes for, 308,092 against, 488,175 abstentions, and 3,056,966 broker non-votes.","An advisory vote on named executive officer compensation passed with 5,572,378 votes for and 788,423 against, plus 3,056,966 broker non-votes.","Approval of a grant of 10,204 Series A Convertible Preferred Shares to Anil Diwan in connection with his employment extension passed with 5,508,079 votes for, 844,079 against.","Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending June 30, 2024 passed with 9,165,259 votes for, 152,847 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":39614008.95428572,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}